甲状腺结节患者的处理:考虑GLP-1受体激动剂
本文综述GLP-1受体激动剂(GLP1RA)与甲状腺癌风险的相关证据。美国食品药品监督管理局黑框警告建议有甲状腺髓样癌或2型多发性内分泌腺瘤病个人或家族史者禁用GLP1RA;新兴数据提示分化型甲状腺癌发生率可能增加,但其他研究未证实关联。目前对GLP1RA治疗前筛查及治疗中评估甲状腺癌的最佳方案尚无明确共识。
要点
- 美国食品药品监督管理局黑框警告建议有甲状腺髓样癌或2型多发性内分泌腺瘤病个人或家族史者不使用GLP1RA。
- 新兴数据提示GLP1RA治疗患者分化型甲状腺癌发生率增加,但其他研究未证实该关联。
- GLP1RA治疗前筛查及治疗中评估甲状腺癌的最佳方案尚无明确共识。
核心结论
- 关于GLP1RA与甲状腺癌风险的结果存在矛盾,对GLP1RA治疗前筛查及治疗中评估甲状腺癌的最佳方案尚无明确共识。
研究设计与样本
- 本文为综述,在患者病例背景下总结现有数据、描述持续存在的争议并勾勒未来研究方向。
主要发现
- 基于啮齿类临床前研究,对GLP1RA诱导C细胞肿瘤的风险存在担忧。
- 美国食品药品监督管理局黑框警告建议有甲状腺髓样癌或2型多发性内分泌腺瘤病2A或2B型个人或家族史者不使用GLP1RA。
- 新兴数据提示接受这些药物治疗的患者分化型甲状腺癌发生率增加,但其他研究未证实GLP1RA与分化型甲状腺癌之间的关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucagon-like peptide 1 receptor agonists (GLP1RAs) have rapidly changed the landscape of diabetes and obesity treatment. Enthusiasm for their use is tempered with concerns regarding their risk for inducing C-cell tumors based on preclinical studies in rodents. A black-box warning from the US Food and Drug Administration recommends against using GLP1RA in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2A or 2B (MEN2), providing clear guidance regarding this cohort of patients. However, emerging data also suggest an increased incidence of differentiated thyroid cancer (DTC) in patients treated with these agents. Other studies, though, have not confirmed an association between GLP1RAs and DTC. With conflicting results concerning thyroid cancer risk, there is no clear consensus regarding the optimal approach to screening patients prior to initiating the medications and/or evaluating for thyroid cancer during GLP1RA treatment. Within the context of patient cases, this review will summarize the existing data, describe ongoing controversies, and outline future areas for research regarding thyroid cancer risk with GLP1RA use.
引用
- Kelly CA, Sipos JA. Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists. J Clin Endocrinol Metab. 2025. PMID: 39400117. doi:10.1210/clinem/dgae722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。